Search

Your search keyword '"Target therapies"' showing total 254 results

Search Constraints

Start Over You searched for: Descriptor "Target therapies" Remove constraint Descriptor: "Target therapies" Search Limiters Full Text Remove constraint Search Limiters: Full Text
254 results on '"Target therapies"'

Search Results

1. The Role of Tumor Biomarkers in Tailoring the Approach to Advanced Ovarian Cancer.

2. Outcomes of Radiotherapy in Oligoprogressive Breast Cancer.

3. Highlights on Future Treatments of IPF: Clues and Pitfalls.

4. Glioma Stem Cells as Promoter of Glioma Progression: A Systematic Review of Molecular Pathways and Targeted Therapies.

5. CD44: A New Prognostic Marker in Colorectal Cancer?

6. Principles in the Management of Glioblastoma.

7. Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors

8. Advancing the Management of Skull Base Chondrosarcomas: A Systematic Review of Targeted Therapies.

9. A Systematic Review of the Metabolism of High-Grade Gliomas: Current Targeted Therapies and Future Perspectives.

10. Advancing Craniopharyngioma Management: A Systematic Review of Current Targeted Therapies and Future Perspectives.

11. Optimizing the Continuum of Care in Gastric Cancer.

12. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.

13. "De Novo" Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature.

14. Targeting FGFR Pathways in Gastrointestinal Cancers: New Frontiers of Treatment.

15. Overview on the Link Between the Complement System and Auto-Immune Articular and Pulmonary Disease

17. Salivary glands adenoid cystic carcinoma: a molecular profile update and potential implications.

18. Immunotherapy for diffuse large B-cell lymphoma: current use of immune checkpoint inhibitors therapy.

20. Salivary glands adenoid cystic carcinoma: a molecular profile update and potential implications

21. Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA.

23. Ovarian cancer – where are we today?

24. MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.

25. Impact of Oral Mesenchymal Stem Cells Applications as a Promising Therapeutic Target in the Therapy of Periodontal Disease.

26. Prevention and Therapy of Metastatic HER-2 + Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine.

27. Precision medicine: The use of tailored therapy in primary immunodeficiencies

28. Targeting FGFR Pathways in Gastrointestinal Cancers: New Frontiers of Treatment

29. Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents.

30. Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa—Possibilities and Limitations.

31. Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study.

32. Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study

33. Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia.

34. Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors.

35. Navigating the autophagic landscape: Epigenetic modulation in gastrointestinal cancer.

36. Bullous Pemphygoid and Novel Therapeutic Approaches

37. Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine

38. Progress of MRI Radiomics in Hepatocellular Carcinoma

39. Progress of MRI Radiomics in Hepatocellular Carcinoma.

40. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.

41. Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia

42. The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects

43. The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects.

44. The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now?

45. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma

46. DNMT3A and DNMT3B Targeting as an Effective Radiosensitizing Strategy in Embryonal Rhabdomyosarcoma

47. The Importance of microRNAs in RAS Oncogenic Activation in Human Cancer

48. Oligonucleotides—A Novel Promising Therapeutic Option for IBD

49. Approaches and challenges in cancer immunotherapy pathways.

50. The role of L1CAM as predictor of poor prognosis in stage I endometrial cancer: a systematic review and meta-analysis.

Catalog

Books, media, physical & digital resources